Turkey
Tuberculosis profile
Population  2013 75 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.31 (0.18–0.48) 0.42 (0.24–0.65)
Mortality (HIV+TB only) 0.01 (<0.01–0.013) 0.01 (0.01–0.02)
Prevalence  (includes HIV+TB) 17 (7.9–30) 23 (11–39)
Incidence  (includes HIV+TB) 15 (14–17) 20 (19–22)
Incidence (HIV+TB only) 0.076 (0.073–0.076) 0.1 (0.1–0.1)
Case detection, all forms (%) 88 (78–92)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 2.5 (2.1–3) 18 (15–21)
MDR-TB cases among notified pulmonary
TB cases
190 (160–230) 160 (130–190)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 5 975   533
Pulmonary, clinically diagnosed 1 816   115
Extrapulmonary 4 561   170
       
Total new and relapse 13 170    
Previously treated, excluding relapses 239    
Total cases notified 13 409    
Among 13 170 new and relapse cases:
581 (4%) cases aged under 15 years; male:female ratio: 1.4
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 4 947 (83%) 592 (56%) 5 539
Laboratory-confirmed RR-/MDR-TB cases     283
Patients started on MDR-TB treatment     228
TB/HIV 2013 Number (%)
TB patients with known HIV status 8 787 (66)
HIV-positive TB patients 32 (<1)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 11 (34)
HIV-positive TB patients on antiretroviral therapy (ART) 20 (63)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate (%)
New cases registered in 2012 88
Previously treated cases registered in 2012 66
HIV-positive TB cases, all types, registered in 2012 51
RR-/MDR-TB cases started on second-line treatment in 2011 66
XDR-TB cases started on second-line treatment in 2011 100
Laboratories 2013  
Smear (per 100 000 population) 0.5
Culture (per 5 million population) 10.2
Drug susceptibility testing (per 5 million population) 5.3
Sites performing Xpert MTB/RIF 19
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2014  
National TB programme budget (US$ millions)  
% Funded domestically  
% Funded internationally  
% Unfunded  
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-03-27 Data: www.who.int/tb/data